Serological cross reactivity between polyomavirus capsids

Advances in Experimental Medicine and Biology

Volumn 577, Issue , 2006, Pages 73-84

  Viscidi, Raphael P ^a   Clayman, Barbara ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

CHEMISTRY; CROSS REACTION; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; POLYOMA VIRUS; REVIEW; VIRUS CAPSID; VIRUS INFECTION;

ANTIBODIES, VIRAL; CAPSID; CROSS REACTIONS; HUMANS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS;

EID: 33745617952     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-32957-9_5     Document Type: Review

References (42)

1. Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol 1999; 19:193-200.
2. Reploeg MD, Storch GA, Clifford DB. Bk virus: A clinical review. Clin Infect Dis 2001; 33:191-202.
3. Hirsch HH. Polyomavirus BK nephropathy: A (re)emerging complication in renal transplantation. Am J Transplant 2002; 2:25-30.
4. Shah K, Nathanson N. Human exposure to SV40: Review and comment. Am J Epidemiol 1976; 103:1-12.
5. Strickler HD, Goedert JJ. Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer - a review of the epidemiological evidence. Dev Biol Stand 1998; 94:235-244.
6. Shah KV. Does SV40 infection contribute to the development of human cancers? Rev Med Virol 2000; 10:31-43.
7. Garcea RL, Imperiale MJ. Simian virus 40 infection of humans. J Virol 2003; 77:5039-5045.
8. Carbone M, Pass HI, Miele L et al. New developments about the association of SV40 with human mesothelioma Oncogene. 2003; 22:5173-5180.
9. Vilchez RA, Kozinetz CA, Arrington AS et al. Simian virus 40 in human cancers. Am J Med 2003; 114:675-684.
10. Takemoto KK, Segawa K. A new monkey lymphotropic papovavirus: Characterization of the virus and evidence of a related virus in humans. Prog Clin Biol Res 1983; 105:87-96.
11. Brade L, Muller-Lantzsch N, zur HH. B-lymphotropic papovavirus and possibility of infections in humans. J Med Virol 1981; 6:301-308.
12. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000; 38:105-109.
13. Shah KV, Daniel RW, Warszawski RM. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. J Infect Dis 1973; 128:784-787.
14. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127:467-470.
15. Knowles WA, Gibson PE, Gardner SD. Serological typing scheme for BK-like isolates of human polyomavirus. J Med Virol 1989; 28:118-123.
16. Minor P, Pipkin P, Jarzebek Z et al. Studies of neutralising antibodies to SV40 in human sera. J Med Virol 2003; 70:490-495.
17. Viscidi RP, Rollison DE, Viscidi E et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 2003; 10:278-285.
18. Chang D, Fung CY, Ou WC et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 1997; 78:435-1439.
19. Goldmann C, Petry H, Frye S et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: Formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999; 73:4465-4469.
20. Hale AD, Bartkeviciute D, Dargeviciute A et al. Expression and antigenic characterization of the major capsid proteins of human polyomaviruses BK and JC in Saccharomyces cerevisiae. J Virol Methods 2002; 104:93-98.
21. Kosukegawa A, Arisaka F, Takayama M et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim Biophys Acta 1996; 1290:37-45.
22. Sandalon Z, Oppenheim A. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 1997; 237:414-421.
23. Sasnauskas K, Buzaite O, Vogel F et al. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 1999; 380:381-386.
24. Pawlita M, Muller M, Oppenlander M et al. DNA encapsidation by viruslike particles assembled in insect cells from the major capsid protein VP1 of B-lymphotropic papovavirus. J Virol 1996; 70:7517-7526.
25. An K, Gillock ET, Sweat JA et al. Use of the baculovirus system to assemble polyomavirus capsid-like particles with different polyomavirus structural proteins: Analysis of the recombinant assembled capsid-like particles. J Gen Virol 1999; 80:1009-1016.
26. Li TC, Takeda N, Kato K et al. Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses. Virology 2003; 311:115-124.
27. Viscidi RP, Ahdieh-Grant L, Clayman B et al. Serum immunoglobulin G response to human papillomavirus type 16 virus- like particles in human immunodeficiency virus (HIV)-positive and risk- matched HIV-negative women. J Infect Dis 2003; 187:194-205.
28. Shah KV. Polyomaviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippencott-Raven Publishers, 1996:2027-2043.
29. Stolt A, Sasnauskas K, Koskela P et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84:1499-1504.
30. Shah KV, McCrumb Jr FR, Daniel RW et al. Serologic evidence for a simian-virus-40-like infection of man. J Natl Cancer Inst 1972; 48:557-561.
31. Gerber P. Patterns of antibodies to SV40 in children following the last booster with inactivated poliomyelitis vaccines. Proc Soc Exp Biol Med 1967; 125:1284-1287.
32. Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71:115-123.
33. Rollison DEM, Helzlsouer KJ, Alberg AJ et al. Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. Cancer Epidemiol Biomarkers Prev 2003; 12:460-463.
34. Jafar S, Rodriguez-Barradas M, Graham DY et al. Serological evidence of SV40 infections in HIV-infected and HIV- negative adults. J Med Virol 1998; 54:276-284.
35. Basetse HR, Lecatsas G, Gerber LJ. An investigation of the occurrence of SV40 antibodies in South Africa S Afr Med J 2002; 92:825-828.
36. de Sanjose S, Shah KV, Domingo-Domenech E et al. Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer 2003; 104:522-524.
37. Carter JJ, Madeleine MM, Wipf GC et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003; 95:1522-1530.
38. Brown P, Tsai T, Gajdusek DC. Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol 1975; 102:331-340.
39. zur HH, Gissmann L. Lymphotropic papovaviruses isolated from African green monkey and human cells. Med Microbiol Immunol 1979; 167:137-153.
40. Kanda T, Yoshiike K, Takemoto KK. Alignment of the genome of monkey B-lymphotropic papovavirus to the genomes of simian virus 40 and BK virus. J Virol 1983; 46:333-336.
41. Pawlita M, Clad A, zur HH. Complete DNA sequence of lymphotropic papovavirus: Prototype of a new species of the polyomavirus genus. Virology 1985; 143:196-211.
42. Takemoto KK, Furuno A, Kato K et al. Biological and biochemical studies of African green monkey lymphotropic papovavirus. J Virol 1982; 42:502-509.